Youssif Abo Elseud MBBCh, MSc, SCE, ESMO
@dr-youssif.bsky.social
Egyptian 🇪🇬 oncologist based in the UK 🇬🇧, treating Thoracic 🫁🩻 and Gynae🦹♀️🧞♀️ cancers ♋️
#OncSky #medSky
#OncSky #medSky
notebooklm.google.com/notebook/7fc...
AI really takes education to a crazy level, I've uploaded this pdf to NotebookLM website from Google, and it generated this audio track of 2 people discussing the article 🫡
Unleashing power of AI 🤞
AI really takes education to a crazy level, I've uploaded this pdf to NotebookLM website from Google, and it generated this audio track of 2 people discussing the article 🫡
Unleashing power of AI 🤞
November 18, 2024 at 8:25 PM
notebooklm.google.com/notebook/7fc...
AI really takes education to a crazy level, I've uploaded this pdf to NotebookLM website from Google, and it generated this audio track of 2 people discussing the article 🫡
Unleashing power of AI 🤞
AI really takes education to a crazy level, I've uploaded this pdf to NotebookLM website from Google, and it generated this audio track of 2 people discussing the article 🫡
Unleashing power of AI 🤞
The intriguing overall survival results of the PRIMA trial
Will this affect our treatment paradigm? 🤷♂️
Will this affect our treatment paradigm? 🤷♂️
November 17, 2024 at 11:48 PM
The intriguing overall survival results of the PRIMA trial
Will this affect our treatment paradigm? 🤷♂️
Will this affect our treatment paradigm? 🤷♂️
Excellent summary of Relevant Clinical Trials With Adjuvant and Neoadjuvant Immunotherapy Components in Resectable NSCLC.
Should we adopt peri-operative approach rather than neoadjuvant pathways? 🫁
Should we adopt peri-operative approach rather than neoadjuvant pathways? 🫁
November 17, 2024 at 11:40 PM
Excellent summary of Relevant Clinical Trials With Adjuvant and Neoadjuvant Immunotherapy Components in Resectable NSCLC.
Should we adopt peri-operative approach rather than neoadjuvant pathways? 🫁
Should we adopt peri-operative approach rather than neoadjuvant pathways? 🫁
"VTE during NACTx chemotherapy for ovarian cancer"
1 in 5 patients undergoing neoadjuvant chemotherapy diagnosed with VTE.
1 in 9 diagnosed after commencing chemotherapy.
leading to delay to treatment and mortality.
Justifies the consideration of thromboprophylaxis.
Do you use Khorana score!!
1 in 5 patients undergoing neoadjuvant chemotherapy diagnosed with VTE.
1 in 9 diagnosed after commencing chemotherapy.
leading to delay to treatment and mortality.
Justifies the consideration of thromboprophylaxis.
Do you use Khorana score!!
November 17, 2024 at 11:30 PM
"VTE during NACTx chemotherapy for ovarian cancer"
1 in 5 patients undergoing neoadjuvant chemotherapy diagnosed with VTE.
1 in 9 diagnosed after commencing chemotherapy.
leading to delay to treatment and mortality.
Justifies the consideration of thromboprophylaxis.
Do you use Khorana score!!
1 in 5 patients undergoing neoadjuvant chemotherapy diagnosed with VTE.
1 in 9 diagnosed after commencing chemotherapy.
leading to delay to treatment and mortality.
Justifies the consideration of thromboprophylaxis.
Do you use Khorana score!!
ASCO updated Guideline, Version 2024.2 is now live
Published November 12, 2024
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations.
To me, treating uncommon EGFR mutations (G719X, L861Q, S7681) is still an area of great interest.
Published November 12, 2024
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations.
To me, treating uncommon EGFR mutations (G719X, L861Q, S7681) is still an area of great interest.
November 17, 2024 at 11:04 PM
ASCO updated Guideline, Version 2024.2 is now live
Published November 12, 2024
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations.
To me, treating uncommon EGFR mutations (G719X, L861Q, S7681) is still an area of great interest.
Published November 12, 2024
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations.
To me, treating uncommon EGFR mutations (G719X, L861Q, S7681) is still an area of great interest.